Beta
Trial Radar KI
Die klinische Studie NCT06421740 (REACH-AD) für Atopische Dermatitis ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China (REACH-AD) 1.000 Real-World-Daten Jugendliche Beobachtend

Offene Rekrutierung
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06421740 (REACH-AD) ist eine beobachtungsstudie zur Untersuchung von Atopische Dermatitis und hat den Status offene rekrutierung. Die Studie startete am 7. Juni 2024 und soll 1.000 Teilnehmer aufnehmen. Durchgeführt von AbbVie ist der Abschluss für 1. Juni 2026 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 12. März 2026 aktualisiert.
Kurzbeschreibung
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin.

Upadacitinib is an approved drug for treating AD. Approximately 1000 adolescents and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in up to 40 sites in China.

Participants will receive oral upadacitinib tablets as prescribed by their ph...

Mehr anzeigen
Offizieller Titel

REal-world Utilization and Treatment Target ACHievement With Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis in China

Erkrankungen
Atopische Dermatitis
Weitere Studien-IDs
  • REACH-AD
  • P24-965
NCT-Nummer
NCT06421740
Studienbeginn (tatsächlich)
2024-06-07
Zuletzt aktualisiert
2026-03-12
Studienende (vorauss.)
2026-06
Geplante Rekrutierung
1.000
Studientyp
Beobachtungsstudie
Status
Offene Rekrutierung
Stichwörter
Upadacitinib
Rinvoq
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
Upadacitinib
Participants will receive upadacitinib as prescribed by their physician according to local label.
Nicht zutreffend
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Number of participants with a dose change
Dose change includes: Changed dose, dose escalation or dose tapering.
12 Months
Number of participants with Upadacitinib drug compliance
The participants missed medication, regardless of reason, or incompliance with the prescription as per medical advice are to be recorded in the eDiary, choosing the reason: "Forgot, Self-reduction of medication, interruption because of AE, interruption not due to safety/tolerability, for other reasons". If no eDiary entries are found within 30 days before the visit, the participant will need to complete the following question in ePRO: timely Upadacitinib intake per medical advice in past 30 days (yes/no); if "no", days-off-drug, intentionally or accidentally, and if "intentionally", reason for incompliance with medical prescription.
12 Months
Number of participants with interruption or permanent discontinuation
Interruption: Upadacitinib is temporarily interrupted due to atopic dermatitis disease condition, economic, tolerance, AE, or personal reasons, and the investigator considers there is still possibility of Upadacitinib re-initiating within the patient's study follow-up period. Discontinuation: Upadacitinib is permanently discontinued for safety or any other reasons, and the investigator considers Upadacitinib will not be used again, at least within the participant's study follow-up period.
12 Months
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Kind, Erwachsene, Ältere Erwachsene
Mindestalter
12 Years
Zugelassene Geschlechter
Alle
  • Adolescents (body weight >= 40 kg at the Baseline Visit for patients between >= 12 and < 18 years of age) and adults at the time of enrollment.
  • Clinical diagnosis of moderate to severe atopic dermatitis at the time of enrollment.
  • UPA treatment is indicated for AD and prescribed as per Chinese label / SmPC.
  • The decision to prescribe UPA is made prior to and independent of study participation.
  • The participant should not be treated with UPA prior to this study.
  • Participants who are willing and able to participate in the collection of patient-reported data, including ePROs and eDiary via apps.
  • The participant (legal representative for adolescents) voluntarily signed an informed consent before any study-related activities are conducted.

  • The participant is currently participating in interventional research (not including noninterventional study, observational study, or registry participation).
  • Any circumstances that the investigator believes may limit the patient's participation and compliance with study procedures.
AbbVie logoAbbVie338 aktive klinische Studien zum Erkunden
Zentrale Studienkontakte
Kontakt: Judy Yu, [email protected]
38 Studienstandorte in 1 Ländern

Beijing Municipality

Beijing Anzhen Hospital /ID# 273443, Beijing, Beijing Municipality, 100029, China
Aktiv, nicht rekrutierend
China-Japan Friendship Hospital /ID# 274778, Beijing, Beijing Municipality, 100029, China
Aktiv, nicht rekrutierend
Peking University First Hospital /ID# 274865, Beijing, Beijing Municipality, 100034, China
Aktiv, nicht rekrutierend
Peking Unversity Third hospital /ID# 274864, Beijing, Beijing Municipality, 100191, China
Aktiv, nicht rekrutierend
Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 264193, Beijing, Beijing Municipality, 100730, China
Aktiv, nicht rekrutierend

Fujian

The First Affiliated Hospital Of Fujian Medical University /ID# 268210, Fuzhou, Fujian, 350005, China
Aktiv, nicht rekrutierend
Changgeng Hospital /ID# 268209, Xiamen, Fujian, 361022, China
Offene Rekrutierung

Guangdong

Guangzhou Dermatology Hospital /ID# 271684, Guangzhou, Guangdong, 510095, China
Aktiv, nicht rekrutierend
The Fifth Affiliated Hospital Of Sun Yat-Sen University /ID# 268618, Zhuhai, Guangdong, 519000, China
Offene Rekrutierung

Hainan

Hainan Fifth People's Hospital /ID# 269747, Hainan, Hainan, 200000, China
Offene Rekrutierung

Hebei

Hebei Engineering University Affiliated Hospital /ID# 268660, Handan, Hebei, 200000, China
Offene Rekrutierung

Heilongjiang

The Second Affiliated Hospital Of Harbin Medical University /ID# 270872, Harbin, Heilongjiang, 150001, China
Offene Rekrutierung

Henan

People's Hospital of Henan Province /ID# 269744, Zhengzhou, Henan, 450003, China
Offene Rekrutierung

Hubei

Wuhan Integrated TCM & Western Medicine Hospital（Wuhan No.1 Hospital) /ID# 272374, Wuhan, Hubei, 430022, China
Offene Rekrutierung
Tongji Hospital /ID# 269745, Wuhan, Hubei, 430030, China
Offene Rekrutierung

Hunan

Xiangya Hospital Central South University /ID# 272373, Changsha, Hunan, 410008, China
Aktiv, nicht rekrutierend

Jiangsu

Nanjing Drum Tower Hospital /ID# 268616, Nanjing, Jiangsu, 210008, China
Offene Rekrutierung
Affiliated Hospital Of Nantong University /ID# 269743, Nantong, Jiangsu, 226001, China
Offene Rekrutierung
The First Affiliated Hospital of Soochow University /ID# 269742, Suzhou, Jiangsu, 215006, China
Offene Rekrutierung
The Affiliated Hospital of Xuzhou Medical College /ID# 268208, Xuzhou, Jiangsu, 221006, China
Offene Rekrutierung

Liaoning

Dalian Dermatosis Hospital /ID# 272495, Dalian, Liaoning, 116041, China
Aktiv, nicht rekrutierend
The People's Hospital of Liaoning Province /ID# 268206, Shenyang, Liaoning, 110016, China
Abgeschlossen

Shandong

Shandong Provincial Hospital /ID# 268661, Jinan, Shandong, 250001, China
Offene Rekrutierung
Jining Medical University - Affiliated Hospital /ID# 270873, Jining, Shandong, 272029, China
Offene Rekrutierung
Weifang People'S Hospital /ID# 268659, Weifang, Shandong, 261041, China
Offene Rekrutierung

Shanghai Municipality

Ruijin Hospital /ID# 268658, Shanghai, Shanghai Municipality, 200025, China
Aktiv, nicht rekrutierend
Huashan Hospital Of Fudan University /ID# 270277, Shanghai, Shanghai Municipality, 200040, China
Offene Rekrutierung
Shanghai Sixth People'S Hospital /ID# 268617, Shanghai, Shanghai Municipality, 200233, China
Offene Rekrutierung
Shanghai Skin Disease Hospital /ID# 268657, Shanghai, Shanghai Municipality, 200443, China
Offene Rekrutierung

Sichuan

West China Hospital of Sichuan University /ID# 268313, Chengdu, Sichuan, 610041, China
Aktiv, nicht rekrutierend
Sichuan Provincial People's Hospital /ID# 268314, Chengdu, Sichuan, 610072, China
Offene Rekrutierung
The Affiliated Hospital Of Southwest Medical University /ID# 268207, Luzhou, Sichuan, 646600, China
Offene Rekrutierung

Xinjiang

People's Hospital of Xinjiang Uygur Autonomous Region /ID# 269746, Ürümqi, Xinjiang, 830001, China
Offene Rekrutierung

Yunnan

The First Affiliated Hospital of Kunming Medical College /ID# 273451, Kunming, Yunnan, 650032, China
Offene Rekrutierung

Zhejiang

Zhejiang Provincial Hospital of Chinese Medicine /ID# 268613, Hangzhou, Zhejiang, 310006, China
Offene Rekrutierung
Ningbo No.6 hospital /ID# 268315, Ningbo, Zhejiang, 315040, China
Offene Rekrutierung
Taizhou Central Hospital /ID# 268211, Taizhou, Zhejiang, 318000, China
Offene Rekrutierung
Zhuji People'S Hospital /ID# 268614, Zhuji, Zhejiang, 315000, China
Offene Rekrutierung